Rushed for time? Here is the top 5 Early Stage Venture investors for Biotechnology startups. Scroll down for more information on these investors or to view the rest of the investors.
Name | Website | Stages | Location | Socials |
---|---|---|---|---|
Abingworth | Early Stage Venture, Late Stage Venture, Private Equity | London, England, United Kingdom, Europe | ||
RebelBio | Early Stage Venture, Seed | London, England, United Kingdom, Europe | ||
Wellcome Trust | Early Stage Venture, Late Stage Venture, Private Equity, Seed | London, England, United Kingdom, Europe | ||
UK Innovation & Science Seed Fund | Early Stage Venture, Late Stage Venture, Seed | Harwell, Oxfordshire, United Kingdom, Europe | ||
GM&C Life Sciences Fund | Early Stage Venture, Seed | Alderley Edge, Cheshire, United Kingdom, Europe |
At SeedRound we track over 200,000 investors and over 1,000,000 people who hold key positions in these firms. We use this directory of investors to highlight top employees, LP’s and funding organisations we think deserve more appreciation than they are currently getting.
We’ve ranked the top Biotechnology Early Stage Venture investors in United Kingdom. The companies, startups and institutions listed in this article are all exceptional companies, well worth a follow. We have included links to their websites, socials and CrunchBase (if you’re interested in their financials).
We selected the organisations listed in this article based on:
- Track record
- Executive leadership
- Market share
- Innovation
- ESG rating
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Top Biotechnology Investors & Funds (United Kingdom)
Abingworth
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors. Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.
Stages: Early Stage Venture, Late Stage Venture, Private Equity
Location: London, England, United Kingdom, Europe
Industries: Biotechnology, Health Diagnostics, Medical, Medical Device
Follow:
RebelBio
RebelBio is the London based team of the venture capital firm SOSV. RebelBio specializes in pre-seed investments in BioTech, HealthTech & Life Sciences. It invests broadly in science-based, tech-enabled early stage startups. RebelBio backs 16 companies per year through its 3 months investment programme. During that time founders receive pre-seed funding and hands-on support from the VC team, working closely to de-risk and fast track the growth of their companies. After the programme, startups can get follow-on investment from RebelBio’s fund SOSV, and support to its founders over the following years.
Stages: Early Stage Venture, Seed
Location: London, England, United Kingdom, Europe
Industries: Biotechnology, Finance, Life Science, Venture Capital
Follow:
Wellcome Trust
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Stages: Early Stage Venture, Late Stage Venture, Private Equity, Seed
Location: London, England, United Kingdom, Europe
Industries: Biotechnology, Health Care, Medical, Non Profit
Follow:
UK Innovation & Science Seed Fund
The UK Innovation & Science Seed Fund is backed by the Department for Business, Energy and Industrial Strategy and the Fund’s partners are 9 publicly funded research bodies, including STFC, BBSRC, NERC and Dstl. The Fund is independently managed by venture capital specialist Midven. They help build companies from great science developed in laboratories, science and technology campuses and synthetic biology. They hold investments in some of the UK’s most innovative companies, in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.
Stages: Early Stage Venture, Late Stage Venture, Seed
Location: Harwell, Oxfordshire, United Kingdom, Europe
Industries: Biotechnology, Financial Services, Venture Capital
Follow:
GM&C Life Sciences Fund
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers (“Catapult Ventures”). The Fund is based at Alderley Park, which is well recognised as a site of national importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca. Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Stages: Early Stage Venture, Seed
Location: Alderley Edge, Cheshire, United Kingdom, Europe
Industries: Biotechnology, Finance, Financial Services, Venture Capital
Follow:
LifeArc
LifeArc is an independent life science medical research charity committed to drastically improving positive patient outcomes everywhere. It specializes in the fields of biotechnology, healthcare, and medical. It was founded in 1992 and headquartered in London, England.
Stages: Early Stage Venture
Location: London, England, United Kingdom, Europe
Industries: Biotechnology, Health Care, Medical
Follow:
Chord Capital
Chord Capital is an independent venture investor, owned by its partners John Townsend and David Farmer. It is based in Cambridge and London. Chord Capital is a highly focused developer of selected post development-stage businesses seeking to commercialise their products. They emphasise manufacture, scale-up and commercialisation of technologies.
Stages: Early Stage Venture
Location: Thrapston, Northamptonshire, United Kingdom, Europe
Industries: Biotechnology, Commercial
Follow:
International Biotechnology Trust
International Biotechnology Trust offers investors access to the fast growing biotechnology sector through an actively managed, diversified fund. Its award winning fund managers at SV Health Investors are scientifically and medically trained with over 60 years of experience in this specialist sector between them. As well as investing in a wide ranging portfolio of global quoted biotechnology stocks, they include a small proportion of otherwise inaccessible carefully selected unquoted investments which have the potential to deliver additional returns over the long term. Excellent management teams, unique innovative products and strong potential for outperformance are the key criteria for inclusion in their diversified portfolio of assets. International Biotechnology Trust offers investors the rare combination of high capital growth and sustainable dividend income. The Lead Investment Manager, Carl Harald Janson is celebrating his five year tenure with strong performance versus the benchmark, significantly outperforming the NBI on both a NAV and share price basis, with outperformances of 10.9% and 43.4% respectively. The NAV has also substantially outperformed the FTSE All-Share Index over the same period, with a return of 142.0% vs the index return of 44.1%.
Stages: Early Stage Venture
Location: London, England, United Kingdom, Europe
Industries: Biotechnology, Finance, Financial Services
Follow:
Kohli Ventures
Tej Kohli is a growth and impact investor focused on ventures that are pioneering the new technologies of the artificial intelligence economy including machine learning, robotics and smart sensor technologies. Through the Kohli Ventures investment vehicle Tej Kohli seeks to make impact investments that can have a humanitarian as well as a commercial impact. Tej Kohli is also Europe’s largest individual investor into the global esports mega trend. The Kohli Ventures investment vehicle is funded entirely by the private capital of the Kohli family without any third-party investors or debt. Kohli Ventures engages exclusively in private business activities and transactions. Our mission is to discreetly back ambitious entrepreneurs and deep tech ventures that have a clear path toward exponential growth as well as having a meaningful human or social impact by solving major global challenges. Kohli Ventures is privately held so the majority of investments within the portfolio are not disclosed within the public domain. A limited number of investments which have attracted publicity include a $100m commitment to the ‘Rewired’ fund in 2019, which encompasses a robotics-focused venture studio and an esports venture fund. In 2010 Kohli Ventures also publicly backed an M&A roll up in the private healthcare sector in the USA; and in 2014 Kohli Ventures publicly acquired DynaCart, a leading global e-commerce company. Kohli Ventures has also led the buyout and turnaround of a B2B SaaS platform technology provider which currently employs over 300 software developers across eight countries. And in 2015 Kohli Ventures publicly backed a renewable energy company in South East Asia that provided off-grid solar products to bring clean and renewable devolved power generation to thousands of poor homes. Tej Kohli is a vocal advocate of the potential for artificial intelligence to become omnipresent and has already committed over $100m of his own money into unlocking and mastering the technologies of the AI revolution. Tej Kohli has previously predicted that the global AI economy could be worth $150 trillion and his investment thesis is that after a process of democratisation, AI will permeate and improve every aspect of human life. Therefore today Kohli Ventures seeks to invest in new and novel frontier technologies from the world of deep tech that can leverage from the anticipated exponential growth in artificial intelligence whilst also offering new opportunities to solve global health and humanitarian challenges. This thesis extends to novel new applications and combinations of existing technologies that can drive a ‘double bottom line’ of financial and human benefit. Kohli Ventures also invests in biotechnology and medical devices and is currently invested in a portfolio of biotech ventures and associated intellectual property in the fields of regenerative medicine, bio synthetics, fluid replacement and diagnostics. Kohli Ventures is also the lead backer of Detraxi, a US-based biotechnology company that has developed a proprietary solution which could solve some major global health challenges. The Detraxi technology has completed trials at Johns Hopkins University and has already secured a pre-market licencing deal in Asia that has an estimated value of more than $50 million. The status of Kohli Ventures as an investor of liquid capital on behalf of a single family is reflected in a risk appetite to back biotechnology ventures to whom traditional capital sources are inaccessible. Biotechnology requires a lot of patience and an appetite for risk that excludes most institutional sources of investment funds from participating. Kohli Ventures seeks to back biotech ventures with a clear pathway to transformational impact. As the investment vehicle of Tej Kohli, Kohli Ventures is also Europe’s largest individual investor into Esports. As the global esports competitive gaming phenomenon becomes the world’s largest spectator sport and with new esports super stars emerging on the global stage, Kohli Ventures continues to invest in exponential growth ventures in what is already a billion dollar global industry. As one of the world’s most prominent esports investors, Kohli Ventures is committed to creating one of the world’s first billion-dollar esports teams. With annual revenue growth in excess of 25%, the global esports market has surpassed $1 billion in revenue and is on track to reach $1.8 billion by 2020. Esports is a spectator sport with estimated global audiences of between 300 and 700 million. Notable investors into esports include David Beckham, Michael Jordan, Drake and Robert Kraft. As a Distinguished Alumni of the Indian Institute of Technology, Tej Kohli has always been fascinated by emerging new technologies. Tej Kohli enjoyed his contemporary success between 1999 and 2006 when he built a global business that grew exponentially by serving high risk industries thanks to its proprietary fraud protection software. Drawing from this experience and the major liquidity event of 2006, Tej Kohli has since mentored up-and-coming young entrepreneurs, many of whom have gone on to build their own successful businesses. Tej is extremely proud of this legacy of the Kohli Ventures mentorship programme, and today Tej Kohli continues to back innovative founders. A proportion of the investment income of Kohli Ventures is donated to the not-for-profit Tej Kohli Foundation. Through its commitment to rebuild people and communities around the world the Tej Kohli Foundation is developing solutions to major global challenges whilst also making direct interventions that change lives. The Tej Kohli Cornea Institute also provides free treatment and cures to thousands of the world’s poorest people each year; whilst the Cornea Program and Applied Research program are leading international efforts to develop an adorable, scalable and accessible solution to ending poverty-driven corneal blindness. Tej Kohli regularly shares wisdom, insight and thoughts about key issues from the world of philanthropy and social impact investment on his Medium blog. He also shares his thoughts on Twitter, Facebook and Instagram using the tag #TejTalks. In 2020 Tej Kohli released ‘Rebuilding You: The Philanthropy Handbook’ as guide for wealth creators who are seeking to help other people by rebuilding people and communities around the world.
Stages: Early Stage Venture, Late Stage Venture, Private Equity
Location: London, England, United Kingdom, Europe
Industries: Artificial Intelligence, Biotechnology, eSports, Machine Learning, Renewable Energy, Robotics, Venture Capital
Follow:
Future Care Capital
In pursuance of its charitable mission, Future Care Capital (FCC) will use its resources to identify and support innovation through the launch of a dedicated Innovation Fund. The Innovation Fund aims to help address major healthcare needs, such as mental health, ageing and living with chronic medical conditions, by investing in innovative enterprises. It will also have an ethical investment policy that will drive its activities in compliance with the charity’s policies and aims. The Fund will invest in UK based, early-stage, high-tech, high-growth enterprises in the field of digital health (including machine learning and AI), assisted living, services and Class I medical devices.
Stages: Early Stage Venture, Seed, Venture
Location: London, England, United Kingdom, Europe
Industries: Biotechnology, Health Care, Life Science, Medical, Pharmaceutical
Follow: